For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 60,263 | |||
| General and administrative | 28,719 | |||
| Total operating expenses | 88,982 | |||
| Loss from operations | -88,982 | |||
| Interest income | 13,295 | |||
| Other income | 419 | |||
| Total other income | 13,714 | |||
| Net loss | -75,268 | |||
| Unrealized gain on marketable securities | 172 | |||
| Total other comprehensive gain | 172 | |||
| Comprehensive loss | -75,096 | |||
| Basic EPS | -1.88 | |||
| Diluted EPS | -1.88 | |||
| Basic Average Shares | 39,962,163 | |||
| Diluted Average Shares | 39,962,163 | |||
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)